Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cell Cycle, Informa UK Limited, Vol. 13, No. 23 ( 2014-12), p. 3727-3741
    Type of Medium: Online Resource
    ISSN: 1538-4101 , 1551-4005
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2014
    detail.hit.zdb_id: 2102687-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 127, No. 17 ( 2016-04-28), p. 2131-2143
    Abstract: Normal ABL1 is a tumor suppressor in BCR-ABL1–induced leukemia. Allosteric stimulation of the normal ABL1 kinase activity enhanced the antileukemia effect of ABL1 tyrosine kinase inhibitors.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3129-3129
    Abstract: Expression of the BCR-ABL1 kinase causes chronic myeloid leukemia in chronic phase (CML). BCR-ABL1 modulates DNA repair mechanisms leading to genomic instability causing resistance to the tyrosine kinase inhibitors and/or disease transition from chronic phase to more malignant stages. BCR-ABL1 –mediated downregulation of breast cancer type 1 susceptibility (BRCA1) protein, a key element in homologous recombination repair (HRR) of DNA double-strand breaks (DSB) was first observed by Deutsch et al, Blood 2003 and later confirmed in our laboratories (Wolanin et al, Mol Cancer Ther 2010; Cramer-Morales et al, Blood 2013). In addition to HRR, BRCA1 protein has been implicated in a broad range of cellular processes, including cell cycle control, cell division and gene transcription (Wu et al, Protein Cell 2010; Moiola et al, Cell Physiol Biochem 2012). We previously reported that downregulation of BRCA1 protein affected the function of spindle assembly checkpoint and postmitotic checkpoint leading to aneuploidy and resistance to spindle poisons in CML cells (Wolanin et al). Recently we also showed that BRCA1-dependent defects in DSB repair in CML cells can sensitize them to synthetic lethality induced by RAD52 inhibitor (Cramer-Morales et al). The mechanism of BRCA1 downregulation in CML cells remained unknown. We observed that it was not due to decreased BRCA1 mRNA expression or shortened protein half-life (Piwocka et al, InTech Press 2011), and it was partially reversible by inhibition of BCR-ABL1 kinase by imatinib (Deutsch et al; Wolanin et al). In addition, mutations abrogating the expression of BRCA1 protein have not been detected in CML (Friedenson, BMC Cancer 2007). Here we report that downregulation of BRCA1 protein is paradoxically associated with enhanced half-life and increased levels of BRCA1 mRNA in a BCR-ABL1 transformed cell line and in CML primary cells. Using polysome profiling and luciferase-BRCA1 3’UTR reporter system we demonstrated that downregulation of BRCA1 protein in BCR-ABL1 expressing cells is caused by inhibition of BRCA1 mRNA translation. We show that this is not accompanied by increased protein degradation. Altogether, these results implicated the involvement of mRNA binding proteins such as Hu protein R (HuR) and TIA1 cytotoxic granule-associated RNA-binding protein-like 1 (TIAR) proteins because of their capability to bind the AU-Rich Element (ARE) sites in 3’UTR of human BRCA1 mRNA. It has been reported that in breast cancer HuR can regulate BRCA1 mRNA stability by binding to its 3’UTR (Saunus et al, FEBS Lett 2007; Cancer Res 2008). The other ARE-site binding protein – TIAR – is a well characterized translation repressor protein activated by stress which is known to inhibit protein synthesis transiently by formation of translational silent stress granules (Anderson & Kedersha, J Cell Sci 2002). We have described that BCR-ABL1 expression causes ER stress and thus activation of Unfolded Protein Response (UPR) stress-induced pathway (Kusio-Kobialka et al, Cell Cycle 2012) which stimulates TIAR (Kedersha & Anderson, Biochem Soc Trans 2002). We observed that BCR-ABL1 kinase promoted cytosolic localization and formation of the TIAR-HuR complex, which facilitated the association with BRCA1 mRNA. We found that HuR protein positively regulated BRCA1 mRNA stability and translation. Conversely TIAR, which was localized predominantly in the cytosolic stress granules in CML cells, abrogated BRCA1 mRNA translation and downregulated BRCA1 protein level. Altogether, we postulate that TIAR-mediated repression of BRCA1 mRNA translation is responsible for downregulation of BRCA1 protein levels in BCR-ABL1 –positive leukemia cells. This mechanism may contribute to genomic instability and provide justification for targeting PARP1 and/or RAD52 to induce synthetic lethality in “BRCAness” CML and BCR-ABL1 –positive ALL cells. Acknowledgments: We acknowledge Prof. Anne Willis and Dr. Lindsay Wilson for technical help and advice. Prof. Myriam Gorospe for providing plasmid with HuR cDNA. This work was supported by the National Science Centre research grant 2011/01/B/NZ3/02145 to K.P. and the Polish Ministry of Science and Higher Education grants IP2011 043071 and IP2010 032870 to P.P-B. Skorski’s lab was supported by NIH/NCI R01 CA123014. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 118, No. 4 ( 2011-07-28), p. 1062-1068
    Abstract: Chronic myeloid leukemia chronic phase (CML-CP) CD34+ cells contain numerous DNA double-strand breaks whose unfaithful repair may contribute to chromosomal instability and disease progression to blast phase (CML-BP). These phenomena are often associated with the appearance of imatinib-resistant BCR-ABL1 kinase mutants (eg, T315I) and overexpression of BCR-ABL1. Here we show that BCR-ABL1 (nonmutated and T315I mutant) promoted RAD51 recombinase-mediated unfaithful homeologous recombination repair (HomeoRR) in a dosage-dependent manner. BCR-ABL1 SH3 domain interacts with RAD51 proline-rich regions, resulting in direct phosphorylation of RAD51 on Y315 (pY315). RAD51(pY315) facilitates dissociation from the complex with BCR-ABL1 kinase, migrates to the nucleus, and enhances formation of the nuclear foci indicative of recombination sites. HomeoRR and RAD51 nuclear foci were strongly reduced by RAD51(Y315F) phosphorylation-less mutant. In addition, peptide aptamer mimicking RAD51(pY315) fragment, but not that with Y315F phosphorylation-less substitution, diminished RAD51 foci formation and inhibited HomeoRR in leukemia cells. In conclusion, we postulate that BCR-ABL1 kinase-mediated RAD51(pY315) promotes unfaithful HomeoRR in leukemia cells, which may contribute to accumulation of secondary chromosomal aberrations responsible for CML relapse and progression.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Clinical Investigation, American Society for Clinical Investigation, Vol. 127, No. 6 ( 2017-5-8), p. 2392-2406
    Type of Medium: Online Resource
    ISSN: 0021-9738 , 1558-8238
    Language: English
    Publisher: American Society for Clinical Investigation
    Publication Date: 2017
    detail.hit.zdb_id: 2018375-6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Cell Reports, Elsevier BV, Vol. 23, No. 11 ( 2018-06), p. 3127-3136
    Type of Medium: Online Resource
    ISSN: 2211-1247
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 2649101-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Society of Hematology ; 2009
    In:  Blood Vol. 114, No. 22 ( 2009-11-20), p. 3272-3272
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 3272-3272
    Abstract: Abstract 3272 Poster Board III-1 CD34+ chronic myeloid leukemia (CML) stem/progenitor cells from chronic phase (CML-CP) and blast crisis (CML-BC) and cell lines transformed by non-mutated BCR/ABL kinase or the tyrosine kinase inhibitor (TKI)-resistant mutants contain numerous DNA double-strand breaks (DSBs) induced by reactive oxygen species (ROS) and genotoxic stress. In addition CD34+CD38- CML-CP and CD34+ CML-BC stem cell-enriched populations seem to display more DSBs than normal counterparts. DSBs may cause apoptosis if not repaired or chromosomal aberrations if repaired unfaithfully. We reported that numerous ROS- and radiation- induced DSBs induce chromosomal instability implicating enhanced, but unfaithful repair in BCR/ABL-positive leukemias [Leukemia, 2008]. We show here that BCR/ABL kinase (non-mutated and TKI-resistant mutants) facilitate recombination repair (RR) of DSBs. Although recombination usually represents a faithful mechanism of DSB repair, it may generate chromosomal aberrations when similar (homeologous), but not identical (homologous) templates are employed during the repair. To study unfaithful homeologous recombination repair (HomeoRR) a reporter repair cassette containing I-SceI endonuclease-;inducible DSB site and a repair template displaying 19% divergence sequence relative to the DSB site was integrated into the genome of 32Dcl3 murine hematopoietic cells and BCR/ABL-positive counterparts. BCR/ABL kinase caused about 3-fold increase in HomeoRR activity implicating its role in accumulation of chromosomal aberrations in CML cells. RAD51, a key regulator of recombination repair, forms a complex with BCR/ABL which depends on the proline- rich (PP) regions of RAD51 and the SH3 domain and SH2-catalytic domain (SH2-CD) linker of BCR/ABL. SH3+SH2-CD domains of BCR/ABL form a pocket binding the PP regions of RAD51. Single amino acid substitutions in the BCR/ABL SH3+SH2-CD pocket, which disrupted binding to the RAD51 PP regions reduced complex formation with RAD51. 32Dcl3 murine hematopoietic cells expressing BCR/ABL SH3+SH2-CD pocket mutant displayed slow proliferation rate and responded poorly to genotoxic stress despite intact kinase activity. On the other hand, disruption of the PP regions of RAD51 by P-L amino acid substitutions (PP-LL mutants) prevented its interaction with BCR/ABL SH3+SH2-CD pocket. Interestingly, expression of RAD51 PP-LL mutant abrogated the clonogenic capability of BCR/ABL-transformed leukemia cells, without any toxic effect on normal counterparts. BCR/ABL-RAD51 complex results in direct phosphorylation of RAD51 on Y315, which is located in the vicinity of PP motifs in the C-terminal portion (aa 271–339) of RAD51. C-terminal Y315F mutant formed more abundant complex with BCR/ABL that the wild-type form, but it did not restore the lost interaction of the PP/LL mutant. Thus, BCR/ABL-mediated RAD51[Y315] phosphorylation appears to be important for disassembly of RAD51 from BCR/ABL. In concordance, RAD51[Y315F] mutant remained mostly in the cytoplasm, while the wild-type protein accumulated in the nucleus in BCR/ABL-positive cells in response to DSBs induced by genotoxic treatment. In addition to the regulation of BCR/ABL-RAD51 interaction, phospho-Y315 is located in a critical fragment of RAD51 essential for its filament formation on DSBs, implicating its direct role in recombination. To test this hypothesis we employed a peptide aptamer strategy targeting phospho-Y315 of RAD51. Peptides corresponding to the RAD51 fragment containing phospho-Y315, but not these with Y315F substitution reduced HomeoRR activity by approximately 2-fold in BCR/ABL-positive leukemia cells. Altogether, it appears that PP-regions of RAD51 interact with SH3+SH2-CD niche of BCR/ABL, which leads to phosphorylation of RAD51 on Y315 and disassembly of the complex. Phospho-Y315 stimulates abundant nuclear localization of RAD51 on DSBs, which disrupts the mechanisms responsible for preventing recombination using divergent templates resulting in unfaithful HomeoRR in BCR/ABL-positive leukemia cells. In summary, BCR/ABL-RAD51 interaction promotes survival and accumulation of chromosomal aberrations of CML cells expressing non-mutated and TKI-resistant BCR/ABL kinase. We hypothesize that targeting BCR/ABL-RAD51 interaction may prevent/delay accumulation of secondary chromosomal aberrations and CML-BC progression. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 4111-4111
    Abstract: Burkitt lymphoma/leukemia (BL) is a highly aggressive mature B-cell neoplasm characterized by chromosomal rearrangements of the c-myc oncogene resulting in the overexpression of MYC transcription factor. The most common translocation is the t(8;14)(q24;q32) (85% of all cases), which involves MYC and IGH loci to generate IGH/MYC. Deregulation of MYC, a potent proto-oncogene and transcriptional regulator contributes to lymphomagenesis through alterations in cell cycle regulation, and cell differentiation, apoptosis, adhesion, and metabolism. BL treatment consists of high-intensity chemotherapy protocols that include cyclophosphamide, cytarabine (AraC) and doxorubicin. Current therapies have achieved a very favorable outcome resulting in complete remission in 75% to 90% of BL patients and a survival rate of 70% to 80%. However the current treatment for BL is suboptimal in elderly patients or patients with advanced-stage diseased, in the setting of HIV infections, as well as in the setting of relapsed disease. Therefore new therapeutic strategies are necessary to improve the outcomes in BL diseases in the poor prognosis patients. It has been reported that overexpression of MYC caused accumulation of potentially lethal DNA double-strand breaks (DSBs), which can modulate the response of tumor cells to genotoxic treatment. Therefore, we examined the consequences of DSBs accumulation in IGH/MYC-positive BL cells. Here we show that untreated and cytarabine (AraC)-treated IGH/MYC-positive BL cells accumulate high number of potentially lethal DNA double-strand breaks (DSBs) and display downregulation of BRCA2 tumor suppressor protein, which is a key element of homologous recombination - mediated DSB repair. BRCA2 deficiency in IGH/MYC-positive cells was associated with hypersensitivity to PARP1 inhibitors (olaparib, talazoparib) used alone or in combination with cytarabine in vitro. Moreover, talazoparib exerted a therapeutic effect in NGS mice bearing primary BL xenografts. In conclusion, we postulate that BRCA2 deficiency may predispose BL cells to synthetic lethality triggered by PARP1 inhibitor, such as recently FDA approved olaparib. Moreover, PARP1 inhibitor may be useful for the treatment of other malignancies associated with deregulation of MYC, including diffuse large B-cell lymphoma (DLBCL) and ALK-positive LBCL. Disclosures Wasik: Gilead Sciences: Equity Ownership; Seattle Genetics: Honoraria; Novartis: Research Funding; University of Pennsylvania: Patents & Royalties: NPM-ALK as an omncogene; University of Pennsylvania: Patents & Royalties: CAR T-cells; Gilead Sciences: Research Funding; Pharmacyclics: Research Funding.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Society of Hematology ; 2010
    In:  Blood Vol. 116, No. 21 ( 2010-11-19), p. 3405-3405
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 3405-3405
    Abstract: Abstract 3405 Background: BCR-ABL1 encoding for oncogenic tyrosine kinase results from t(9;22)(q34;q11) reciprocal translocation or variants generating the Philadelphia chromosome (Ph), which initiates chronic myeloid leukemia in chronic phase (CML-CP). The second (wild-type) ABL1 and BCR alleles in CML-CP cells remain intact on the non-rearranged homologues of chromosome 9 and 22, respectively. Accordingly, CML-CP cells at early stages express both forms of the ABL1 kinase, oncogenic BCR-ABL1 and normal ABL1. ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib revolutionized the treatment of CML-CP, but they do not eradicate leukemia. Patients who do achieve complete cytogenetic remission (CCyR) may eventually stop responding and acquire resistance to TKIs, which may lead to disease relapse and malignant progression. Mutations in the sequence encoding BCR-ABL1 kinase have been detected in approximately 50% of CML-CP patients resistant to TKIs, but other factors contributing to this phenomenon are poorly characterized. Results: Here, we identified a novel mechanism of TKI resistance: loss of the remaining normal ABL1 allele resulting from cryptic deletion in the 9q34 region in the normal chromosome 9 [del(9)(q34)]. Using bacterial artificial chromosome probes (BACs) for dual color/dual probe fluorescent in situ hybridization (D-FISH), and oligonucleotide array comparative genomic hybridization (aCGH) we show that genomic deletion of ABL1 allele in non-translocated chromosome 9 acquired during TKI therapy in CML-CP patients was associated with resistance to imatinib and dasatinib. del(9)(q34) was detected in approximately 10% of the patients who initially failed to achieve CCyR within 12 months of TKI treatment. Moreover, BCR-ABL1-positive Abl1-/- murine leukemia cells were refractory to imatinib in comparison to BCR-ABL1–positive Abl1+/+ counterparts as indicated by persistent BCR-ABL1 –mediated tyrosine phosphorylation, lack of BCR-ABL1 protein degradation, increased cell survival and clonogenic activity. Expression of exogenous ABL1 kinase in BCR-ABL1–positive Abl1-/- cells restored their sensitivity to imatinib. These results provide direct evidence that Abl1 plays a crucial role in regulation of the sensitivity of BCR-ABL1-positive leukemia cells to imatinib. ABL1 is regarded as a cell cycle regulatory and pro-apoptotic protein, thus antagonistic to BCR-ABL1. The cell cycle inhibitory activity is independent of ABL1 kinase, whereas the pro-apoptotic function is dependent on its kinase activity. However, acquired resistance to TKIs caused by a loss of the wild-type ABL1 kinase does not appear to depend directly on the lack of ABL1-induced cell cycle arrest and/or apoptosis. In contrast to BCR-ABL1 –positive Abl1+/+ leukemia cells, imatinib exerted only modest effect on BCR-ABL1 kinase-dependent tyrosine phosphorylation and did not downregulate BCR-ABL1 protein in Abl1-/- leukemia cells, suggesting the role of Abl1 in cellular uptake of the drug and/or BCR-ABL1 degradation. Expression of imatinib cellular importer Oct-1 and cellular exporters Abcb1 and Abcg2 does not appear to favor the resistance to TKI in BCR-ABL1-positive Abl1-/- cells, but the impact of ABL1 on intracellular metabolism of imatinib cannot be excluded. In addition, expression of chaperone protein Hsp90, which protects BCR-ABL1 from proteasomal degradation, is not affected by Abl1. However, 〉 3-fold downregulation of cathepsin B may be responsible for lack of degradation of BCR-ABL1 protein in imatinib-treated Abl1-/- cells. Conclusions: Altogether, it can be postulated that loss of expression of ABL1 kinase plays an important role in TKI resistance in CML. It can be achieved by interstitial deletion in chromosome 9 [del(9)(q34)] causing loss of normal ABL1 allele, which could be eventually combined with epigenetic silencing of the alternative ABL1 promoter retained in the CpG island of the BCR-ABL1 gene in t(9;22)(q34:q11). Detection of the del(9)(q34) is beyond the resolution of conventional karyotyping currently used to monitor TKI treatment response. In contrast, D-FISH using commercially available probes can identify such loss in both quiescent and dividing cells. In summary, downregulation of ABL1 caused by del(9)(q34) may serve as an important prognostic factor and have a significant impact on CML treatment. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 1190-1190
    Abstract: Abstract 1190 Background: CD34+ chronic myeloid leukemia (CML) stem/progenitor cells from chronic phase (CML-CP) and blast phase (CML-BP) and cell lines transformed by non-mutated BCR-ABL1 kinase or tyrosine kinase inhibitor (TKI)-resistant mutants contain numerous DNA double-strand breaks (DSBs) induced by reactive oxygen species (ROS) (Nowicki et al., Blood, 2006; Cramer et al., Cancer Res., 2008). DSBs may cause apoptosis if not repaired or chromosomal aberrations if repaired unfaithfully. We reported that numerous ROS and radiation induced DSBs generated chromosomal aberrations in BCR-ABL1-positive leukemia cells (Koptyra et al., Leukemia, 2008), which may contribute to the malignant progression to CML-BP. We also showed that homologous recombination repair (HomoRR) driven by RAD51 recombinase is one of the major DSB repair mechanisms, which is stimulated by BCR-ABL1 (Slupianek et al., Molecular Cell, 2001). Although recombination usually represents a faithful mechanism of DSB repair, it may generate chromosomal aberrations when similar (homeologous), but not identical (homologous) templates are employed during the repair. Here we investigated if BCR-ABL1 can modulate RAD51 recombinase to corrupt the fidelity of recombination and if this process can be targeted to prevent genomic instability in leukemia cells. Result: To study unfaithful homeologous recombination repair (HomeoRR) a reporter repair cassette containing I-SceI endonuclease–inducible DSB site and a repair template displaying 1% sequence divergence relative to the DSB site was integrated into the genome of 32Dcl3 murine hematopoietic cells, BCR-ABL1-32Dcl3 cells and BCR-ABL1(T315I)-32Dcl3 cells. BCR-ABL1 and BCR-ABL1(T315I) kinase caused about a 3-fold increase in HomeoRR activity implicating its role in the accumulation of chromosomal aberrations in CML cells. The magnitude of HomeoRR stimulation depended on BCR-ABL1 expression levels. RAD51 recombinase, a key regulator of recombination repair, forms a complex with BCR-ABL1 which depends on the proline- rich (PP) regions of RAD51 and the SH3 domain of BCR-ABL1, but does not depend on its kinase activity. In fact, BCR-ABL1(K1172R) kinase-dead mutant formed complexes more abundantly with RAD51 than the kinase-active BCR-ABL1. BCR-ABL1-RAD51 complex formation resulted in direct phosphorylation of RAD51 on Y315 [RAD51(phosphoY315)], which is located in the vicinity of PP motifs in the C-terminal portion of RAD51. Phosphorylation-less C-terminal RAD51(Y315F) mutant formed a stronger complex with BCR-ABL1 than the wild-type form. Altogether, it appears that RAD51 PP bind to the SH3 domain of BCR-ABL1 kinase followed by quick phosphorylation of RAD51 on Y315 and disassembly of RAD51(phosphoY315) from the complex. Y315 is located in a critical fragment of RAD51 essential for its filament formation on DSBs, implicating its direct role in recombination. In fact RAD51(phosphoY315) was found in the nuclei of BCR-ABL1 leukemia cells, but not of parental cells and formed numerous foci on DSBs. Phosphorylation-less RAD51(Y315F) mutant abrogated foci formation and inhibited HomeoRR. Thus, BCR-ABL1 – RAD51(phosphoY315) pathway appears to promote unfaithful HomeoRR and chromosomal instability. To test if RAD51(phosphoY315) can be targeted to prevent unfaithful HomeoRR in leukemia cells, a peptide aptamer strategy was applied. Aptamer mimicking the RAD51(phosphoY315) fragment, but not that with the Y315F phosphorylation-less substitution inhibited RAD51 foci formation and HomeoRR activity in BCR-ABL1 leukemia cells. Conclusion: In summary, the BCR-ABL1-RAD51 axis may promote accumulation of chromosomal aberrations of CML cells expressing non-mutated and TKI-resistant BCR-ABL1 kinase. We hypothesize that targeting BCR-ABL1-RAD51 interaction may prevent/delay accumulation of secondary chromosomal aberrations and CML-BP progression. Furthermore, RAD51 and recombination is also affected by other oncogenic tyrosine kinases (OTKs) such as TEL-ABL1, TEL-PDGFR, ZNF198-FGFR1, TEL-JAK2, JAK2[V617F], NPM-ALK, IGF-1R, EGFR and FLT3-ITD suggesting that abrogation of OTK-mediated aberrant modulation of RAD51 may inhibit genetic instability and tumor progression. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages